Crinetics Pharmaceuticals’ Post

Crinetics announces the randomization of the first patient in a Phase 3 trial of an investigational treatment being studied in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. Read more: https://bit.ly/3X6kKcn